Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations
Ching Kuo Tan, Gui Quan Say, James B Geake Department of Respiratory Medicine, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia Abstract: Tiotropium bromide is a long-acting inhaled muscarinic antagonist used in patients with chronic respiratory disease. It has been available since 2002 as a sin...
Main Authors: | Tan CK, Say GQ, Geake JB |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-09-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/long-term-safety-of-tiotropium-delivered-by-respimatreg-softmisttrade--peer-reviewed-article-TCRM |
Similar Items
-
Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®
by: Dekhuijzen PNR, et al.
Published: (2016-08-01) -
Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
by: S. K. Zyryanov, et al.
Published: (2018-04-01) -
A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01) -
Bronchodilator efficacy of 18 µg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial
by: Yildiz P, et al.
Published: (2016-11-01) -
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
by: LaForce C, et al.
Published: (2018-06-01)